Cigna is cutting weight-loss GLP-1 coverage for its own employees, and that makes the obesity drug boom look less simple for everyone building around it
Am J Gastroenterol 119(6):10281037 Osei SP, Akomaning E, Florut TF, Sodhi M, Lacy BE, Aldhaleei WA, Bhagavathula AS (2024) Gastrointestinal safety assessment of GLP-1 receptor agonists in the US: a real-world adverse events analysis from the FAERS database
Gastrointestinal issues, including nausea, vomiting, diarrhea and headaches, are commonly reported side effects of GLP-1s, according to the Mayo Clinic
These results demonstrate the long-term anti-obesity and anti-diabetic effects achieved from a single in vivo genome editing treatment
Cinnamon extract and ginger support healthy glucose levels, and essential nutrients thiamin and chromium help convert glucose into energy